Duowell® + Telmisartan
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypertension
Conditions
Hypertension, Dyslipidemia
Trial Timeline
Sep 11, 2017 → Sep 2, 2020
NCT ID
NCT03267329About Duowell® + Telmisartan
Duowell® + Telmisartan is a approved stage product being developed by Yuhan for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT03267329. Target conditions include Hypertension, Dyslipidemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03267329 | Approved | Completed |
Competing Products
20 competing products in Hypertension
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85